Evidence-based policy improvements for lipid lowering therapy: a focus on reducing clinical inertia and improving cardiovascular outcomes

INTRODUCTION: Despite substantial evidence linking low-density lipoprotein cholesterol (LDL-C) reduction to improved cardiovascular outcomes, a significant implementation gap persists. Clinical inertia, defined as failure to initiate or intensify therapy despite suboptimal control, remains a key barrier to achieving guideline-recommended LDL-C goals, particularly in high-risk populations. AREAS COVERED: This review analyses systemic drivers of clinical inertia in lipid management, with emphasis on modifiable policy and organizational barriers. These include restrictive access and reimbursement policies, suboptimal health information technology and workflow design, misaligned quality metrics, and fragmented care delivery models. Evidence-based strategies to address these barriers are evaluated, including administrative reform, financial incentives, integrated clinical decision support, team-based care, and structured care pathways. EXPERT OPINION: The principal challenge is not therapeutic efficacy but effective implementation. Translating evidence into population benefit requires a shift from isolated prescribing to system-level optimization. Key priorities include harmonizing access policies with guidelines, embedding outcome-based accountability, and scaling multidisciplinary care models. Sustained adherence also depends on addressing patient-level beliefs, treatment tolerability and burden, and broader socio-economic barriers, including social determinants of health. Over the next five years, progress will depend on integrating implementation science, digital tools, and value-based frameworks to enable proactive, equitable, and sustainable lipid control.